CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
Kinetic profiling of RAS mutations with circulating tumor DNA - CO26
Purpose: In metastatic colorectal cancer (mCRC), RAS mutations drive resistance to anti-epidermal growth factor receptor antibodies. It is unclear whether RAS mutations ever become clonally undetectable.
The Canadian led HE1 trial results, published in Lancet Oncology, confirm the quality-of-life benefits of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver meta
The CCTG NE2 STOPNET neuroendocrine study has officially open in Canada. Researchers are investigating whether somatostatin analogues (SSA) are needed after targeted therapy for patients with neuroendocrine tumours.
“NE2 addresses an important question for patients and the healthcare system of whether we can reduce treatment burden by stopping SSAs after PRRT has been completed,” says Dr Jonathan Loree, the NE2 study co-chair and BC Cancer Oncologist.
The Canadian Cancer Trials Group (CCTG) at Queens University is currently seeking a visionary cancer trialist for the position of Senior Investigator (SI). The new SI will play a critical role for CCTG, acting as a co-principal investigator of numerous individual trials and a leader within the CCTG program and scientific committees.
As part of our commitment to promote capacity building in the Canadian cancer research landscape, the CIHR Institute of Cancer Research (CIHR-ICR), in partnership with the Ontario Institute for Cancer Research and Terry Fox Research Institute, as well as in-kind partners, the Canadian Cancer Society and Cancer Research Society, is pleased to announce the open call for applications for its annual Early Career Researcher (ECR) Workshop.
